Mustang Bio (MBIO) Common Equity (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Common Equity of $8.6 million for Q1 2026, up 138.18% year-over-year from $3.6 million in Q1 2025, and down 9.79% quarter-over-quarter from $9.5 million in Q4 2025.
Mustang Bio (MBIO) Common Equity (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Common Equity for 11 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 138.18% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $8.6 million (up 138.18% YoY), while the FY2025 annual figure was $9.5 million, up 346.04% from the prior year.
- Common Equity retreated to $8.6 million in Q1 2026 per MBIO's latest filing, from $9.5 million in the prior quarter.
- Across five years, Common Equity topped out at $97.3 million in Q1 2022 and bottomed at -$8.7 million in Q3 2024.
- Historically, Common Equity has averaged $20.4 million across 5 years, with a median of $8.6 million in 2026.
- Annual changes were most pronounced in 2024 — Common Equity plunged 3248.78% — and 2025, when it surged 346.04%.
- Mustang Bio's Common Equity stood at $46.3 million in 2022, then plunged by 99.73% to $123000.0 in 2023, then slumped by 3248.78% to -$3.9 million in 2024, then jumped by 346.04% to $9.5 million in 2025, then slipped by 9.79% to $8.6 million in 2026.
- Business Quant data shows MBIO's Common Equity at $8.6 million in Q1 2026, $9.5 million in Q4 2025, and $9.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 9.79 Bn |
| 10 | Mustang Bio | 3.86 Mn | 3.86 Mn | - | 7.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.55 Mn |
| Mar 31, 2026 | 8.60 Mn |
| Dec 31, 2025 | 9.53 Mn |
| Sep 30, 2025 | 9.77 Mn |
| Jun 30, 2025 | 2.89 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Dec 31, 2024 | -3.87 Mn |
| Sep 30, 2024 | -8.66 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -4.94 Mn |
| Dec 31, 2023 | 123,000.00 |
| Sep 30, 2023 | 4.01 Mn |
| Jun 30, 2023 | 13.71 Mn |
| Mar 31, 2023 | 29.82 Mn |
| Dec 31, 2022 | 46.27 Mn |
| Sep 30, 2022 | 64.33 Mn |
| Jun 30, 2022 | 82.01 Mn |
| Mar 31, 2022 | 97.33 Mn |
| Dec 31, 2021 | 112.40 Mn |
| Sep 30, 2021 | 122.21 Mn |